Şunu aradınız:: virologic (İngilizce - Danca)

virologic rebound
virologisk reboundd pga opståen af etvrc

virologic non response
virologisk non-respons†

sustained virologic response
vedvarende virologisk respons

responsesustained virologic response 100
respons ved afsluttet vedvarende virologisk respons behandling 94% (211/224) 81% (182/224)

on- treatment virologic failure
virologisk svigt under behandling

lead to loss of virologic response
fører til tab af virologisk respons og

absence of prior virologic failure
intet tidligere virologisk svigt

no virologic data at weeks 48 window
ingen virologiske data i analysevinduet omkring uge 48

total number of virologic failuresa, n (%)
samlet antal virologiske svigta, n (%)

c - genotypic etvr with virologic d breakthrough a
- genotype etvrc med virologisk gennembrud a

sustained virologic response 81% (182/224)
hcv 2 600. 000 iu/ml 600. 000 iu/ml

virologic response rate was evaluated in both treatment arms.
virologisk responsrate blev evalueret i begge behandlingsarme.

virologic failure (hiv rna >200 copies/ml)
virologisk svigt (hiv- rna > 200 kopier/ml)

virologic response of study subjects at week 48 study 802
forsøgspersonernes virologisk respons ved uge 48 studie 802

sustained virologic response 81% (182/224)relapse
hcv 2 600. 000 iu/ml

intent-to-treat time to loss of virologic response.
intent-to-treat time to loss of virologic response.

no subjects experienced on-treatment virologic failure or relapse.
ingen forsøgspersoner oplevede virologisk svigt under behandlingen eller recidiv.

c - genotypic etvr with virologic d breakthrough cumulative probability of:
- genotype- etvrc med virologisk gennembrud kumulativ sandsynlighed for:

virologic success (48 weeks hiv rna < 50 copies/ml)
virologisk succes (48 ugers hiv-rna < 50 kopier/ml)

close monitoring of patient's virologic response should be exercised.
patientens virologiske respons bør følges tæt.